ROIVANT SCIENCES LTD. Accrued Liabilities, Current
ROIVANT SCIENCES LTD. (ROIV) had Accrued Liabilities, Current of $168.74 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accrued Liabilities, Current $168.74M.
- 2026-03-31: Accrued Liabilities, Current $205.82M.
- 2025-12-31: Accrued Liabilities, Current $117.99M.
- 2025-09-30: Accrued Liabilities, Current $108.31M.
| Period end | Accrued Liabilities, Current | Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $168.74M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $205.82M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $117.99M 10-Q · filed 2026-02-06 | |
| 2025-09-30 | $108.31M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $88.73M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $114.29M 10-K · filed 2026-05-20 | |
| 2024-12-31 | $104.32M 10-Q · filed 2025-02-10 | |
| 2024-09-30 | $111.47M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $138.29M 10-Q · filed 2024-08-09 | |
| 2024-03-31 | $119.42M 10-K · filed 2025-05-29 | $175.59M 10-K · filed 2024-05-30 |
| 2023-12-31 | $122.15M 10-Q · filed 2024-02-13 | |
| 2023-09-30 | $152.92M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $119.33M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $167.13M 10-K · filed 2024-05-30 | |
| 2022-12-31 | $132.36M 10-Q · filed 2023-02-13 | |
| 2022-09-30 | $128.81M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $109.35M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $127.53M 10-K · filed 2023-06-28 | |
| 2021-12-31 | $112.68M 10-Q · filed 2022-02-14 | |
| 2021-09-30 | $104.11M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $73.79M 10-Q · filed 2021-09-21 | |
| 2021-03-31 | $76.94M 10-K · filed 2022-06-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |